Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG

Abstract

A method of treating amyloid-beta peptide aggregation in a subject includes contacting at least one amyloid-beta peptide oligomer formed from a plurality of amyloid-beta peptide monomers with a composition containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12. The effective amount of vitamin B12 being sufficient to stimulate dissociation of the amyloid-beta peptide monomers from the at least one amyloid-beta peptide oligomer. The composition may be used to treat amyloidosis, including Alzheimer's disease.

That which is claimed is: 
     
         1 . A method of treating amyloid-beta peptide aggregation in a human having Alzheimer's disease, the method comprising:
 determining a first level of amyloid-beta peptides in the human;   establishing a first dose of vitamin B12 based on the first level of amyloid-beta peptides in the human, the first dose being sufficient to cause dissociation of amyloid-beta peptide monomers from amyloid-beta peptide aggregates in the human; and   administering a pharmaceutically acceptable dosage form to the human, the dosage form containing the first dose of vitamin B12 in combination with melatonin, resveratrol, and EGCG.   
     
     
         2 . The method of  claim 1 , wherein determining the first level of amyloid-beta peptides in the human includes testing the human's plasma for an amount of amyloid-beta peptides therein. 
     
     
         3 . The method of  claim 1 , wherein the amount of vitamin B12 in the first dose is at least equimolar with a molarity of amyloid-beta peptides in the first level of amyloid-beta peptides. 
     
     
         4 . The method of  claim 1 , further comprising:
 determining a second level of amyloid-beta peptides in the human after administering the first dose;   establishing a second dose of vitamin B12 based on the second level of amyloid-beta peptides in the human; and   administering the second dose to the human.   
     
     
         5 . The method of  claim 4 , wherein the amount of vitamin B12 in the second dose is at least equimolar with a molarity of amyloid-beta peptides in the second level of amyloid-beta peptides. 
     
     
         6 . A method of treating amyloid-beta peptide aggregation in a subject, the method comprising contacting at least one amyloid-beta peptide oligomer formed from a plurality of amyloid-beta peptide monomers with a composition containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12, the effective amount of vitamin B12 being sufficient to stimulate dissociation of the amyloid-beta peptide monomers from the at least one amyloid-beta peptide oligomer. 
     
     
         7 . The method of treating amyloid-beta peptide aggregation of  claim 6 , wherein the effective amount is a function of a quantity of amyloid-beta peptides in a sample taken from the subject. 
     
     
         8 . The method of treating amyloid-beta peptide aggregation in a subject of  claim 7 , wherein the sample is a portion of the subject's plasma. 
     
     
         9 . The method of treating amyloid-beta peptide aggregation in a subject of  claim 7 , wherein the effective amount is at least equimolar with a molarity of amyloid-beta peptides estimated to be in the subject based on the quantity of amyloid-beta peptides in the sample. 
     
     
         10 . The method of treating amyloid-beta peptide aggregation in a subject of  claim 6 , wherein the effective amount is at least one molecule of vitamin B12 per amyloid-beta peptide monomer dissociated. 
     
     
         11 . The method of treating amyloid-beta peptide aggregation in the subject of  claim 6 , wherein the subject is identified as having a condition characterized by amyloid-beta peptide aggregates. 
     
     
         12 . A method of treating Alzheimer's disease, the method comprising administering to a human having Alzheimer's disease a pharmaceutically acceptable dosage form containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12, the effective amount of vitamin B12 being sufficient to cause dissociation of amyloid-beta peptide monomers from pre-existing amyloid-beta peptide oligomers in the human, the effective amount being based on a pre-determined quantity of amyloid-beta peptide oligomers in the human. 
     
     
         13 . The method of treating Alzheimer's disease of  claim 12 , wherein the quantity of amyloid-beta peptide oligomers in the patient is estimated from a level of amyloid-beta peptides in a sample of the patient's plasma. 
     
     
         14 . The method of treating Alzheimer's disease of  claim 13 , wherein the effective amount is at least an equimolar ratio of vitamin B12 to amyloid-beta peptides in the sample. 
     
     
         15 . A method of treating an amyloidosis, the method comprising:
 administering to a human having an amyloidosis a pharmaceutically acceptable dosage form containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12, the effective amount of vitamin B12 being sufficient to cause dissociation of amyloid-beta peptide monomers from pre-existing amyloid-beta peptide oligomers in the human.   
     
     
         16 . The method of  claim 15 , wherein the effective amount of vitamin B12 is a function of a pre-determined quantity of amyloid-beta peptide oligomers in the human. 
     
     
         17 . The method of  claim 15 , wherein the quantity of amyloid-beta peptide oligomers in the human is estimated from a level of amyloid-beta peptides in a sample of the human's plasma. 
     
     
         18 . The method of  claim 15 , wherein the effective amount of vitamin B12 is at least an equimolar ratio of vitamin B12 to amyloid-beta peptides in a sample of the human's plasma. 
     
     
         19 . The method of  claim 15 , wherein the amyloidosis is Alzheimer's disease.